forest laboratories

Duncan-Williams, which raised its PT on shares of Forest Laboratories Inc. (NYSE: FRX), is providing some color on the stock. “In a recent SEC filing Forest disclosed that the Icahn parties held 7.20% of the outstanding common stock (fourth largest shareholder behind Wellington, Vanguard, and...

Duncan Williams has raised the price target on Forest Laboratories (NYSE: FRX) from $40 to $45 and maintains its Buy rating.

Colgate-Palmolive (NYSE: CL) and Forest Laboratories (NYSE: FRX) reached new 52-week highs of $89.28 and $39.56 per share, respectively, late in Monday's trading session. Colgate just announced the completion of its purchase of the Sanex personal care brand from Unilever (NYSE: UL). Colgate has a...

According to Goldman Sachs, Forest Laboratories (NYSE: FRX) announced it has received notice that High River Limited Partnership, an entity affiliated with Carl Icahn, has taken a 6.5% stake in the company (options and shares) and intends to nominate four individuals for election to Forest's nine-...

CIGNA (NYSE: CI) and Forest Laboratories (NYSE: FRX) reached new 52-week highs of $50.70 and $37.87 per share, respectively, on Thursday but were lower in premarket trading Friday. CIGNA was raised to Outperform as yesterday's Bull of the Day at Zacks. The company has a market cap of $13.6...

J.P. Morgan is out with its report today on Forest Laboratories (NYSE: FRX), maintaining Overweight. In a note to clients, J.P. Morgan writes, "Following the approval of Daliresp and the acquisition of Viibryd earlier this year and ahead of FDA filings for linaclotide and aclidinium as several...

Yesterday, we had a quick look at ten potential takeover targets from a list of 50 offered up recently by Deutsche Bank (NYSE: DB) strategists. Here we glance at another ten from their list of leveraged buyout candidates. Again, the companies on their list have market capitalizations of less than...

J.P. Morgan is out with its report today on Forest Laboratories (NYSE: FRX), upgrading FRX from Neutral to Overweight. In a note to clients, J.P. Morgan writes, "We are upgrading FRX shares to Overweight from Neutral and see an increasingly favorable risk/reward profile for the stock. Our survey...

JP Morgan has upgraded Forest Laboratories (NYSE: FRX) from Neutral to Overweight and has raised the price target from $38 to $41 as a favorable risk/reward profile is being witnessed for the stock.

Jefferies, which raised its PT on shares of Forest Laboratories Inc. (NYSE: FRX), is providing some color on the stock. “FRX has proven its development capability over the last three years and its focus now returns to what it does best – commercial execution. The Street's pessimistic about...

Jefferies & Company has raised the price target on Forest Labs (NYSE: FRX) from $39 to $42 and maintains its Buy rating.

Piper Jaffray has lowered the price target on Forest Laboratories (NYSE: FRX) from $31 to $29 and maintains its Underweight rating.

In its core product and pricing trends for the week ending 3-4-11, Citi is focusing on the following Forest Laboratories, Inc. (NYSE: FRX) products: Lexapro: “~$2.82B Annual Run Rate Implied by 4-Week Average TRx's vs. Our FY'11E US Sales of $2.28B,” Citi writes. “Lexapro posted wkly NRx/TRx of 232...

Jefferies & Company has published a research report on Forest Laboratories (NYSE: FRX) as Jefferies believes that the company will experience no value destruction to shares despite its deep late-stage pipeline operations. In the report, Jefferies writes "Viibryd, CLDA's (NASDAQ: $31.21, NC)...

On 2/22, Forest Laboratories, Inc. (NYSE: FRX) announced an agreement to acquire Clinical Data, Inc. (NASDAQ: CLDA) with the transaction expected complete ~2Q11. “FRX will pay $30.00/sh plus up to $6.00/sh related to Viibryd commercial milestones,” Oppenheimer writes. “At ~2.0x our Viibryd peak...